FCA
SPRY icon

FinTrust Capital Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

FinTrust Capital Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$29K Hold
2,000
– – ﹤0.01% 725
2024
Q2 		$17K Hold
2,000
– – ﹤0.01% 802
2024
Q1 		$20.4K Buy
+2,000
New +$14.9K ﹤0.01% 729

Other funds holding SPRY

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

FinTrust Capital Advisors's SPRY Position: Q3 2024 in Review

FinTrust Capital Advisors held its ARS Pharmaceuticals (SPRY) position steady in Q3 2024 at 2,000 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #725.

FinTrust Capital Advisors first reported a position in SPRY in Q1 2024 and has held it in 3 quarters since. 150 funds tracked by Wall St. Rank hold SPRY as of Q3 2024.

  • FinTrust Capital Advisors held 2,000 shares of ARS Pharmaceuticals worth $29K as of Q3 2024.
  • FinTrust Capital Advisors left its ARS Pharmaceuticals share count unchanged in Q3 2024.
  • ARS Pharmaceuticals made up ﹤0.01% of FinTrust Capital Advisors's portfolio in Q3 2024, its #725 holding.
  • FinTrust Capital Advisors first reported a position in ARS Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • 150 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2024.

Based on FinTrust Capital Advisors's 13F filing for Q3 2024, filed 11 Oct 2024.